MDL 3172: Cartiva Synthetic Cartilage Implant
Official jurisdictional document library tracking Judicial Panel on Multidistrict Litigation (JPML) transfer orders, Conditional Transfer Orders (CTOs), and master docket proceedings in the U.S. District Court for the Eastern District of Arkansas.
Multidistrict Litigation (MDL) No. 3172 was established to consolidate federal product liability lawsuits concerning the Cartiva Synthetic Cartilage Implant (SCI). Marketed as a motion-preserving alternative to fusion for big toe arthritis (hallux rigidus), plaintiffs nationwide allege the polyvinyl alcohol hydrogel implant is defectively designed and prone to early subsidence, loosening, and fragmentation—causing severe pain, osteolysis, and requiring corrective toe fusion surgeries.
Core Case Information
JPML Official Document Library
Procedural History & Timeline
- Late August 2026 Chief Judge Baker convenes the Initial Organizational Meeting, formally approving the Plaintiffs’ Steering Committee and outlining discovery schedules for master pleadings and plaintiff fact sheets.
- June 2026 The court dockets CTO-5 and CTO-6, continuing steady nationwide consolidation. On June 22, Judge Baker enters the formal Letter/Order scheduling the organizational conference.
- April – May 2026 The JPML issues Conditional Transfer Orders CTO-2, CTO-3, and CTO-4 as product liability claims filed in other federal jurisdictions are routed to Little Rock.
- February 2026 On February 5, the JPML enters the Transfer Order establishing MDL 3172. The following day, CTO-1 is entered, and on February 18, the court enters the Order Upon Transfer (Docket No. 5).
Key Panel Findings & Court Leadership
Common Factual Questions Identified by the JPML
In ordering centralization into the Eastern District of Arkansas, the Judicial Panel identified core common factual and legal questions:
- The nature and biomechanical mechanisms causing Cartiva implant subsidence, loosening, and severe bone wear.
- The adequacy of Cartiva’s warnings, instructions for use (IFU), and clinical trial disclosure protocols.
- Representations made to the FDA by Cartiva and Stryker regarding safety profiles and non-inferiority to fusion.
- The circumstances surrounding the Class 2 recall and post-market revision surgery incidence.
Court-Appointed Leadership Structure
- Plaintiffs’ Liaison Counsel: Paul J. James (James & Carter, PLC • Little Rock, AR)
- Plaintiffs’ Co-Lead Counsel: Alex C. Davis (Alex Davis Law Office PSC) & Randi Kassan (Milberg, PLLC)
- Defense Co-Lead & Liaison Counsel: Sean K. Burke & Dana J. Ash (Duane Morris LLP)
NGRV Leadership & Medical Device Litigation
Nigh Goldenberg Raso & Vaughn (NGRV) is actively investigating claims nationwide for patients who received a Cartiva Synthetic Cartilage Implant and suffered implant failure, subsidence, chronic pain, or required corrective revision/fusion surgery. We monitor master docket filings daily to ensure our clients’ interests are protected throughout the multidistrict litigation.
Suffered Complications from a Cartiva Toe Implant?
If you or a loved one underwent surgery with a Cartiva synthetic cartilage implant and suffered implant failure, bone loss, or required corrective toe fusion, you may be entitled to financial compensation. Contact our mass tort attorneys for a free, confidential case review.
